blank Quick help
blank Maintenance news

Scheduled maintenance

Regular maintenance outages:
between 05.00 and 05.15 hrs CET (Monday to Sunday).

Other outages
Availability
Register Forum

2022.02.11

More...
blank News flashes

News Flashes

New version of the European Patent Register – SPC proceedings information in the Unitary Patent Register.

2024-07-24

More...
blank Related links

Release notes
European Patent Register Assistant
European Patent Register Resource Book
European Patent Register – pocket guide
FAQ - European Patent Register
FAQ - Register Alert
Federated Register (Flyer)
Global Dossier (Flyer)
Register events
Deep link coverage
Federated Register content
The Patent Information Tour
Fair use charter

Extract from the Register of European Patents

EP About this file: EP3475284

EP3475284 - PYRROLOBENZODIAZEPINES AND CONJUGATES THEREOF [Right-click to bookmark this link]
StatusNo opposition filed within time limit
Status updated on  08.09.2023
Database last updated on 03.09.2024
FormerThe patent has been granted
Status updated on  30.09.2022
FormerGrant of patent is intended
Status updated on  24.05.2022
FormerExamination is in progress
Status updated on  15.02.2020
FormerRequest for examination was made
Status updated on  29.03.2019
FormerThe international publication has been made
Status updated on  29.12.2017
Formerunknown
Status updated on  12.07.2017
Most recent event   Tooltip24.05.2024Lapse of the patent in a contracting state
New state(s): IT		published on 26.06.2024  [2024/26]
Applicant(s)For all designated states
Mersana Therapeutics, Inc.
840 Memorial Drive
Cambridge, MA 02139 / US
[2019/18]
Inventor(s)01 / THOMAS, Joshua D.
83 Bacon Street
Natick, Massachusetts 01760 / US
02 / YIN, Mao
50 Mount Vernon Street
Needham, Massachusetts 02492 / US
03 / YURKOVETSKIY, Aleksandr
2 Old Farm Road
Littleton, Massachusetts 01460 / US
04 / CONLON, Patrick R.
20 Eaton Street
Wakefield, Massachusetts 01880 / US
05 / HILMY, Ahmed
64 Woburn Street
Lexington, Massachusetts 02420 / US
06 / KELLEHER, Eugene W.
20 Sunnyside Avenue
Wellesley, Massachusetts 02482 / US
07 / LOWINGER, Timothy B.
352 School Street
Carlisle, Massachusetts 01741 / US
08 / STEVENSON, Cheri A.
81 Old Yankee Road
Haverhill, Massachusetts 01832 / US
09 / TANG, Shuyi
1011 Halei Road
Suite 306
Zhangjiang High-tech Park
Pudong New District
Shanghai / CN
 [2019/18]
Representative(s)Cooley (UK) LLP
22 Bishopsgate
London EC2N 4BQ / GB
[2022/44]
Former [2019/18]Cooley (UK) LLP
Dashwood
69 Old Broad Street
London EC2M 1QS / GB
Application number, filing date17734623.622.06.2017
[2019/18]
WO2017US38684
Priority number, dateUS201662354609P24.06.2016         Original published format: US 201662354609 P
US201762486750P18.04.2017         Original published format: US 201762486750 P
[2019/18]
Filing languageEN
Procedural languageEN
PublicationType: A1 Application with search report
No.:WO2017223275
Date:28.12.2017
Language:EN
[2017/52]
Type: A1 Application with search report 
No.:EP3475284
Date:01.05.2019
Language:EN
The application published by WIPO in one of the EPO official languages on 28.12.2017 takes the place of the publication of the European patent application.
[2019/18]
Type: B1 Patent specification 
No.:EP3475284
Date:02.11.2022
Language:EN
[2022/44]
Search report(s)International search report - published on:EP28.12.2017
ClassificationIPC:C07D487/04, A61K31/5517, A61P35/00
[2019/18]
CPC:
C07D243/14 (EP,US); A61K31/5517 (EP,US); A61K47/59 (US);
A61K47/62 (US); A61K47/68035 (EP,US); A61K47/6855 (EP,US);
A61K47/6883 (EP,US); A61P35/00 (EP); C07D487/04 (EP,US);
C08L59/00 (US); C12N15/111 (US); C07C2523/44 (US);
C07C2603/12 (US); C07C2603/22 (US); C07C2603/30 (US) (-)
Designated contracting statesAL,   AT,   BE,   BG,   CH,   CY,   CZ,   DE,   DK,   EE,   ES,   FI,   FR,   GB,   GR,   HR,   HU,   IE,   IS,   IT,   LI,   LT,   LU,   LV,   MC,   MK,   MT,   NL,   NO,   PL,   PT,   RO,   RS,   SE,   SI,   SK,   SM,   TR [2019/18]
Extension statesBANot yet paid
MENot yet paid
Validation statesMANot yet paid
MDNot yet paid
TitleGerman:PYRROLOBENZODIAZEPINE UND KONJUGATE DAVON[2019/18]
English:PYRROLOBENZODIAZEPINES AND CONJUGATES THEREOF[2019/18]
French:PYRROLOBENZODIAZÉPINES ET CONJUGUÉS DE CELLES-CI[2019/18]
Entry into regional phase23.01.2019National basic fee paid 
23.01.2019Designation fee(s) paid 
23.01.2019Examination fee paid 
Examination procedure23.01.2019Examination requested  [2019/18]
23.01.2019Date on which the examining division has become responsible
23.08.2019Amendment by applicant (claims and/or description)
19.02.2020Despatch of a communication from the examining division (Time limit: M06)
26.08.2020Reply to a communication from the examining division
04.12.2020Despatch of a communication from the examining division (Time limit: M04)
14.04.2021Reply to a communication from the examining division
12.08.2021Despatch of a communication from the examining division (Time limit: M04)
21.12.2021Reply to a communication from the examining division
25.05.2022Communication of intention to grant the patent
21.09.2022Fee for grant paid
21.09.2022Fee for publishing/printing paid
21.09.2022Receipt of the translation of the claim(s)
Opposition(s)03.08.2023No opposition filed within time limit [2023/41]
Fees paidRenewal fee
27.06.2019Renewal fee patent year 03
29.06.2020Renewal fee patent year 04
28.06.2021Renewal fee patent year 05
27.06.2022Renewal fee patent year 06
Opt-out from the exclusive  Tooltip
competence of the Unified
Patent Court		 See the Register of the Unified Patent Court for opt-out data
Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court.
Lapses during opposition  TooltipAL02.11.2022
AT02.11.2022
CZ02.11.2022
DK02.11.2022
EE02.11.2022
ES02.11.2022
FI02.11.2022
HR02.11.2022
IT02.11.2022
LT02.11.2022
LV02.11.2022
MC02.11.2022
NL02.11.2022
PL02.11.2022
RO02.11.2022
RS02.11.2022
SE02.11.2022
SI02.11.2022
SK02.11.2022
SM02.11.2022
NO02.02.2023
GR03.02.2023
IS02.03.2023
PT02.03.2023
LU22.06.2023
BE30.06.2023
[2024/26]
Former [2024/24]AL02.11.2022
AT02.11.2022
CZ02.11.2022
DK02.11.2022
EE02.11.2022
ES02.11.2022
FI02.11.2022
HR02.11.2022
LT02.11.2022
LV02.11.2022
MC02.11.2022
NL02.11.2022
PL02.11.2022
RO02.11.2022
RS02.11.2022
SE02.11.2022
SI02.11.2022
SK02.11.2022
SM02.11.2022
NO02.02.2023
GR03.02.2023
IS02.03.2023
PT02.03.2023
LU22.06.2023
BE30.06.2023
Former [2024/15]AL02.11.2022
AT02.11.2022
CZ02.11.2022
DK02.11.2022
EE02.11.2022
ES02.11.2022
FI02.11.2022
HR02.11.2022
LT02.11.2022
LV02.11.2022
MC02.11.2022
NL02.11.2022
PL02.11.2022
RO02.11.2022
RS02.11.2022
SE02.11.2022
SI02.11.2022
SK02.11.2022
SM02.11.2022
NO02.02.2023
GR03.02.2023
IS02.03.2023
PT02.03.2023
LU22.06.2023
Former [2024/09]AL02.11.2022
AT02.11.2022
CZ02.11.2022
DK02.11.2022
EE02.11.2022
ES02.11.2022
FI02.11.2022
HR02.11.2022
LT02.11.2022
LV02.11.2022
MC02.11.2022
NL02.11.2022
PL02.11.2022
RO02.11.2022
RS02.11.2022
SE02.11.2022
SI02.11.2022
SK02.11.2022
SM02.11.2022
NO02.02.2023
GR03.02.2023
IS02.03.2023
PT02.03.2023
Former [2023/51]AL02.11.2022
AT02.11.2022
CZ02.11.2022
DK02.11.2022
EE02.11.2022
ES02.11.2022
FI02.11.2022
HR02.11.2022
LT02.11.2022
LV02.11.2022
NL02.11.2022
PL02.11.2022
RO02.11.2022
RS02.11.2022
SE02.11.2022
SI02.11.2022
SK02.11.2022
SM02.11.2022
NO02.02.2023
GR03.02.2023
IS02.03.2023
PT02.03.2023
Former [2023/38]AL02.11.2022
AT02.11.2022
CZ02.11.2022
DK02.11.2022
EE02.11.2022
ES02.11.2022
FI02.11.2022
HR02.11.2022
LT02.11.2022
LV02.11.2022
NL02.11.2022
PL02.11.2022
RO02.11.2022
RS02.11.2022
SE02.11.2022
SK02.11.2022
SM02.11.2022
NO02.02.2023
GR03.02.2023
IS02.03.2023
PT02.03.2023
Former [2023/37]AL02.11.2022
AT02.11.2022
CZ02.11.2022
DK02.11.2022
EE02.11.2022
ES02.11.2022
FI02.11.2022
HR02.11.2022
LT02.11.2022
LV02.11.2022
NL02.11.2022
PL02.11.2022
RO02.11.2022
RS02.11.2022
SE02.11.2022
SM02.11.2022
NO02.02.2023
GR03.02.2023
IS02.03.2023
PT02.03.2023
Former [2023/35]AT02.11.2022
CZ02.11.2022
DK02.11.2022
EE02.11.2022
ES02.11.2022
FI02.11.2022
HR02.11.2022
LT02.11.2022
LV02.11.2022
NL02.11.2022
PL02.11.2022
RO02.11.2022
RS02.11.2022
SE02.11.2022
SM02.11.2022
NO02.02.2023
GR03.02.2023
IS02.03.2023
PT02.03.2023
Former [2023/34]AT02.11.2022
DK02.11.2022
EE02.11.2022
ES02.11.2022
FI02.11.2022
HR02.11.2022
LT02.11.2022
LV02.11.2022
NL02.11.2022
PL02.11.2022
RS02.11.2022
SE02.11.2022
SM02.11.2022
NO02.02.2023
GR03.02.2023
IS02.03.2023
PT02.03.2023
Former [2023/33]AT02.11.2022
DK02.11.2022
ES02.11.2022
FI02.11.2022
HR02.11.2022
LT02.11.2022
LV02.11.2022
NL02.11.2022
PL02.11.2022
RS02.11.2022
SE02.11.2022
SM02.11.2022
NO02.02.2023
GR03.02.2023
IS02.03.2023
PT02.03.2023
Former [2023/29]AT02.11.2022
ES02.11.2022
FI02.11.2022
HR02.11.2022
LT02.11.2022
LV02.11.2022
NL02.11.2022
PL02.11.2022
RS02.11.2022
SE02.11.2022
NO02.02.2023
GR03.02.2023
IS02.03.2023
PT02.03.2023
Former [2023/25]AT02.11.2022
ES02.11.2022
FI02.11.2022
HR02.11.2022
LT02.11.2022
LV02.11.2022
PL02.11.2022
RS02.11.2022
SE02.11.2022
NO02.02.2023
GR03.02.2023
IS02.03.2023
PT02.03.2023
Former [2023/23]AT02.11.2022
ES02.11.2022
FI02.11.2022
LT02.11.2022
LV02.11.2022
SE02.11.2022
NO02.02.2023
GR03.02.2023
PT02.03.2023
Former [2023/22]AT02.11.2022
ES02.11.2022
FI02.11.2022
LT02.11.2022
SE02.11.2022
NO02.02.2023
PT02.03.2023
Former [2023/20]LT02.11.2022
NO02.02.2023
Cited inInternational search[A]WO2008099416  (COUNCIL SCIENT IND RES [IN], et al);
 [X]WO2013164592  (UCL BUSINESS PLC [GB], et al);
 [XPI]WO2017032983  (FEMTOGENIX LTD [GB]);
 [XPI]WO2017051249  (LEGOCHEM BIOSCIENCES INC [KR]);
ExaminationWO2013164593
by applicantUS4309437
 US5583024
 US5674713
 US5700670
 US5763263
 US7303749
 WO2011013063
 WO2011130616
 WO2011130613
 WO2011130598
 WO2011128650
 WO2012128868
 WO2013041606
 WO2013055993
 WO2013055990
 WO2013053873
 WO2013053871
 WO2013055987
 WO2013164593
 WO2013177481
 WO2014011519
 WO2014011518
 WO2014022679
 WO2014057122
 WO2014057073
 WO2014057074
 WO2014096365
 WO2014096368
 WO2014130879
 WO2014140174
 WO2014174111
 US2015010440
 WO2015023355
 WO2015052535
 WO2015052534
 WO2015052321
 WO2015052322
 US2015133435
 WO2015095227
 WO2015095124
 WO2015159076
 US2016031887
 WO2016037644
 WO2016040723
 WO2016044560
 WO2016044396
The EPO accepts no responsibility for the accuracy of data originating from other authorities; in particular, it does not guarantee that it is complete, up to date or fit for specific purposes.